Cargando…

Efficacy of Phenobarbital and Prognosis Predictors in Women With Epilepsy From Rural Northeast China: A 10-Year Follow-Up Study

OBJECTIVE: To investigate the efficacy of phenobarbital (PB), factors associated with it, reasons for early treatment termination, and mortality rates in adult women living in rural Northeast China. METHODS: A prospective study was conducted in seven counties of Jilin Province from 2010 to 2020. Adu...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Chaojia, Li, Nan, Zhong, Rui, Zhao, Danyang, Lin, Weihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889069/
https://www.ncbi.nlm.nih.gov/pubmed/35250838
http://dx.doi.org/10.3389/fneur.2022.838098
_version_ 1784661311744901120
author Chu, Chaojia
Li, Nan
Zhong, Rui
Zhao, Danyang
Lin, Weihong
author_facet Chu, Chaojia
Li, Nan
Zhong, Rui
Zhao, Danyang
Lin, Weihong
author_sort Chu, Chaojia
collection PubMed
description OBJECTIVE: To investigate the efficacy of phenobarbital (PB), factors associated with it, reasons for early treatment termination, and mortality rates in adult women living in rural Northeast China. METHODS: A prospective study was conducted in seven counties of Jilin Province from 2010 to 2020. Adult women diagnosed with convulsive epilepsy were recruited into the study and baseline demographics recorded upon enrollment. Seizure frequency, prescribed drug dose, and adverse reactions were monitored monthly by door-to-door survey or telephone interview. RESULTS: A total of 1,333 women were included in the study. During the follow-up period, 169 participants (12.7%) were lost to follow-up, and 100 of them (7.5%) died. The percentage of seizure-free participants was 45.3% in the first year, 74.6% in the third year, and 96.6% in the 10th year. A higher baseline seizure frequency (OR = 1.005, 95% CI: 1.002–1.009), more frequent loss-of-consciousness seizures (OR = 1.620, 95% CI: 1.318–1.990), a higher daily dose of PB in the first year (OR = 1.018, 95% CI: 1.014–1.022), a younger age at onset (OR = 0.990, 95% CI: 0.982–0.998), and more severe drowsiness (OR = 1.727, 95% CI: 1.374–2.173) were associated with an increased risk of seizures in the first year, and the higher baseline seizure frequency was still associated with the occurrence of seizures in the third (OR = 1.007, 95% CI: 1.004–1.010) and fifth year (OR = 1.005, 95% CI: 1.002–1.008). Age at enrollment (HR = 0.983, 95% CI: 0.971–0.994) was the only factor that correlated with withdrawal from the study and with the death of the participant during the follow up period, but the correlation in each case was in opposite directions. SIGNIFICANCE: PB has high effectiveness, retention rate, mild side effects, and tolerability when used as a treatment for epilepsy in women from rural areas. Baseline seizure frequency is an important predictor of prognosis regardless of treatment duration. PB is still a valuable tool for the management of epilepsy in adult women from poverty-stricken areas.
format Online
Article
Text
id pubmed-8889069
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88890692022-03-03 Efficacy of Phenobarbital and Prognosis Predictors in Women With Epilepsy From Rural Northeast China: A 10-Year Follow-Up Study Chu, Chaojia Li, Nan Zhong, Rui Zhao, Danyang Lin, Weihong Front Neurol Neurology OBJECTIVE: To investigate the efficacy of phenobarbital (PB), factors associated with it, reasons for early treatment termination, and mortality rates in adult women living in rural Northeast China. METHODS: A prospective study was conducted in seven counties of Jilin Province from 2010 to 2020. Adult women diagnosed with convulsive epilepsy were recruited into the study and baseline demographics recorded upon enrollment. Seizure frequency, prescribed drug dose, and adverse reactions were monitored monthly by door-to-door survey or telephone interview. RESULTS: A total of 1,333 women were included in the study. During the follow-up period, 169 participants (12.7%) were lost to follow-up, and 100 of them (7.5%) died. The percentage of seizure-free participants was 45.3% in the first year, 74.6% in the third year, and 96.6% in the 10th year. A higher baseline seizure frequency (OR = 1.005, 95% CI: 1.002–1.009), more frequent loss-of-consciousness seizures (OR = 1.620, 95% CI: 1.318–1.990), a higher daily dose of PB in the first year (OR = 1.018, 95% CI: 1.014–1.022), a younger age at onset (OR = 0.990, 95% CI: 0.982–0.998), and more severe drowsiness (OR = 1.727, 95% CI: 1.374–2.173) were associated with an increased risk of seizures in the first year, and the higher baseline seizure frequency was still associated with the occurrence of seizures in the third (OR = 1.007, 95% CI: 1.004–1.010) and fifth year (OR = 1.005, 95% CI: 1.002–1.008). Age at enrollment (HR = 0.983, 95% CI: 0.971–0.994) was the only factor that correlated with withdrawal from the study and with the death of the participant during the follow up period, but the correlation in each case was in opposite directions. SIGNIFICANCE: PB has high effectiveness, retention rate, mild side effects, and tolerability when used as a treatment for epilepsy in women from rural areas. Baseline seizure frequency is an important predictor of prognosis regardless of treatment duration. PB is still a valuable tool for the management of epilepsy in adult women from poverty-stricken areas. Frontiers Media S.A. 2022-02-16 /pmc/articles/PMC8889069/ /pubmed/35250838 http://dx.doi.org/10.3389/fneur.2022.838098 Text en Copyright © 2022 Chu, Li, Zhong, Zhao and Lin. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Chu, Chaojia
Li, Nan
Zhong, Rui
Zhao, Danyang
Lin, Weihong
Efficacy of Phenobarbital and Prognosis Predictors in Women With Epilepsy From Rural Northeast China: A 10-Year Follow-Up Study
title Efficacy of Phenobarbital and Prognosis Predictors in Women With Epilepsy From Rural Northeast China: A 10-Year Follow-Up Study
title_full Efficacy of Phenobarbital and Prognosis Predictors in Women With Epilepsy From Rural Northeast China: A 10-Year Follow-Up Study
title_fullStr Efficacy of Phenobarbital and Prognosis Predictors in Women With Epilepsy From Rural Northeast China: A 10-Year Follow-Up Study
title_full_unstemmed Efficacy of Phenobarbital and Prognosis Predictors in Women With Epilepsy From Rural Northeast China: A 10-Year Follow-Up Study
title_short Efficacy of Phenobarbital and Prognosis Predictors in Women With Epilepsy From Rural Northeast China: A 10-Year Follow-Up Study
title_sort efficacy of phenobarbital and prognosis predictors in women with epilepsy from rural northeast china: a 10-year follow-up study
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889069/
https://www.ncbi.nlm.nih.gov/pubmed/35250838
http://dx.doi.org/10.3389/fneur.2022.838098
work_keys_str_mv AT chuchaojia efficacyofphenobarbitalandprognosispredictorsinwomenwithepilepsyfromruralnortheastchinaa10yearfollowupstudy
AT linan efficacyofphenobarbitalandprognosispredictorsinwomenwithepilepsyfromruralnortheastchinaa10yearfollowupstudy
AT zhongrui efficacyofphenobarbitalandprognosispredictorsinwomenwithepilepsyfromruralnortheastchinaa10yearfollowupstudy
AT zhaodanyang efficacyofphenobarbitalandprognosispredictorsinwomenwithepilepsyfromruralnortheastchinaa10yearfollowupstudy
AT linweihong efficacyofphenobarbitalandprognosispredictorsinwomenwithepilepsyfromruralnortheastchinaa10yearfollowupstudy